Leukaemia - acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib for patients with acute lymphoblastic leukaemia.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib under the National Health Act 1953, sections 85 and 100 for patients with acute lymphoblastic leukaemia (ALL).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing blinatumomab, dasatinib, imatinib, inotuzumab ozogamicin and ponatinib.

Section 100 arrangements

Blinatumomab and inotuzumab ozogamicin

These items are only PBS subsidised for day admitted patients, non-admitted patient, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

You must include the hospital name and provider number on the authority application form. These items aren’t PBS subsidised for hospital in-patients.

Applications

Initial treatment

Blintumomab

Apply for authority approval to prescribe initial (induction) PBS subsidised blinatumomab for the treatment of ALL in writing and either:

All applications must include the completed:

Dasatinib

Apply for authority approval to prescribe first line initial PBS subsidised dasatinib to treat ALL in writing and either:

All applications must include the completed:

Apply for authority approval to prescribe second line initial PBS subsidised dasatinib to treat ALL in writing and either:

All applications must include the completed:

Imatinib

Apply for first line initial PBS subsidised imatinib treatment call the PBS Complex Drugs Programs enquiry line.

Inotuzumab ozogamicin

Apply for authority approval to prescribe initial PBS subsidised inotuzumab ozogamicin to treat ALL in writing and either:

All applications must include the completed:

Ponatinib

Apply for authority approval to prescribe initial PBS subsidised ponatinib to treat ALL in writing and either:

All applications must include the completed:

Initial grandfather treatment

Blinatumomab

For patients who received non-PBS subsidised blinatumomab treatment before 1 October 2019 for ALL, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Inotuzumab ozogamicin

For patients who received non-PBS subsidised inotuzumab ozogamicin treatment before 1 May 2019 for ALL, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Ponatinib

For patients who received non-PBS subsidised ponatinib treatment before 1 September 2018 for ALL, apply for initial grandfather authority approval in writing and either:

All applications must include a completed:

Continuing treatment

To apply for continuing PBS subsidised blinatumomab, dasatinib, inotuzumab ozogamicin and ponatinib to treat ALL, call the PBS Complex Drugs Programs enquiry line.

Continuing PBS subsidised treatment with imatinib is Authority Required (Streamlined). It doesn’t need authority approval from us for listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 30 September 2019